MRNS Class Action Alert: Robbins LLP Reminds MRNS Stockholders About the Marinus Pharmaceuticals, Inc. Securities Fraud Class Action

The Allegations: Robbins LLP is Investigating Allegations Marinus Pharmaceuticals, Inc. (MRNS) Misled Investors Regarding the Viability of its Drug Candidate Then, on May 8, 2024, Marinus announced cost cutting measures, including to stop "the Phase 3 Raise II trial in RSE; future development in RSE will be assessed following review of the RAISE topline data[.]" That same day, Fierce Biotech published an article sharing that "Marinus lays off 20% of staff to steady ship after IV seizure med's phase 3 strugg ...